Len Rosen is a senior managing director in the firm’s strategic advisory business and CEO of Evercore Israel.
Mr. Rosen has advised Israeli clients on many of the largest and most important Israeli M&A transactions, including Orbotech’s sale to KLA; RADA Electronics’ merger with Leonardo DRS; Cellwize’s sale to Qualcomm; Cognyte’s spinoff from Verint; Verint’s acquisition of Witness; Ceragon’s defense against a hostile bid by Aviat; multiple acquisitions by Teva Pharmaceuticals, including Barr, Ivax and Sicor; Given Imaging’s sale to Covidien; Fundtech’s sale to D+H; and SuperDerivatives’ sale to ICE.
Mr. Rosen has also been involved in raising over $100 billion in financing for Israel and Israeli companies, including more than 100 cross-border IPOs and equity transactions for tech and healthcare companies and over 60 fixed-income transactions for the sovereign, Israel Electric and the Israeli natural gas sector.
Prior to joining Evercore, he was the CEO of Barclays Israel, and before that was the CEO of Lehman Brothers Israel and a technology banker at Lehman Brothers.
Mr. Rosen began his career as an attorney with Cravath, Swaine & Moore. He has a B.A. from Columbia College and a J.D. from Columbia Law School.